<SEC-DOCUMENT>0001415889-25-003986.txt : 20250214
<SEC-HEADER>0001415889-25-003986.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214112247
ACCESSION NUMBER:		0001415889-25-003986
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88334
		FILM NUMBER:		25625048

	BUSINESS ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frazier Life Sciences Public Fund, L.P.
		CENTRAL INDEX KEY:			0001863769
		ORGANIZATION NAME:           	
		IRS NUMBER:				862999645
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		650-325-5156

	MAIL ADDRESS:	
		STREET 1:		1001 PAGE MILL ROAD
		STREET 2:		BUILDING 4, SUITE B
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
		<previousAccessionNumber>0001193125-24-251059</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001863769</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>1</amendmentNo>
	      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001404281</issuerCik>        <issuerName>Eledon Pharmaceuticals, Inc.</issuerName>        <issuerCusip>28617K101</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>19800 MacArthur Blvd., Suite 250</com:street1>
                    <com:city>Irvine</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92612</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   				        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
		      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>878080.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>878080.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>878080.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.5</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 878,080 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P.  FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.P. </reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>878080.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>878080.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>878080.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.5</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 878,080 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P.  FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>878080.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>878080.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>878080.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.5</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 consist of 878,080 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P.  FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences Public Overage Fund, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>258998.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>258998.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>258998.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 258,998 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP Overage, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>258998.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>258998.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>258998.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.4</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 258,998 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLSP Overage, L.L.C.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>258998.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>258998.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>258998.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.4</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 consist of 258,998 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>13062.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>13062.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>13062.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 13,062 shares of Common Stock held directly by Frazier Life Sciences X, L.P.  FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P.  Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>13062.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>13062.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>13062.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 13,062 shares of Common Stock held directly by Frazier Life Sciences X, L.P.  FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P.  Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>13062.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>13062.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>13062.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 consist of 13,062 shares of Common Stock held directly by Frazier Life Sciences X, L.P.  FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P.  Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>26595.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>26595.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>26595.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 26,595 shares of Common Stock held directly by Frazier Life Sciences XI, L.P.  FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>26595.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>26595.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>26595.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>





	        <typeOfReportingPerson>PN</typeOfReportingPerson>









	  <comments>The shares listed in rows 6, 8 and 9 consist of 26,595 shares of Common Stock held directly by Frazier Life Sciences XI, L.P.  FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>26595.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>26595.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>26595.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>











	        <typeOfReportingPerson>OO</typeOfReportingPerson>



	  <comments>The shares listed in rows 6, 8 and 9 consist of 26,595 shares of Common Stock held directly by Frazier Life Sciences XI, L.P.  FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James N. Topper</reportingPersonName>

	  		<memberGroup>b</memberGroup>


		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1176735.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1176735.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1176735.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of (i) 878,080 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 258,998 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 13,062 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iv) 26,595 shares of Common Stock held directly by Frazier Life Sciences XI, L.P.  FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P.  Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.  FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Patrick J. Heron</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1176735.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1176735.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1176735.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>2.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of (i) 878,080 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 258,998 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iii) 13,062 shares of Common Stock held directly by Frazier Life Sciences X, L.P., and (iv) 26,595 shares of Common Stock held directly by Frazier Life Sciences XI, L.P.  FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P.  Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.  FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Albert Cha </reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1137078.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1137078.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1137078.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.9</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of (i) 878,080 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 258,998 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P.  FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>James Brush</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>1137078.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>1137078.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1137078.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>1.9</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of (i) 878,080 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., and (ii) 258,998 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P.  FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P.  Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Daniel Estes</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>26595.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>26595.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>26595.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>0.0</classPercent>










	        <typeOfReportingPerson>IN</typeOfReportingPerson>




	  <comments>The shares listed in rows 6, 8 and 9 consist of 26,595 shares of Common Stock held directly by Frazier Life Sciences XI, L.P.  FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based on 59,739,275 shares of Common Stock outstanding on November 8, 2024, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024.</comments>

    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>Eledon Pharmaceuticals, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>19800 MacArthur Blvd., Suite 250, Irvine, CA, 92612.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>The entities and persons filing this statement (collectively, the "Reporting Persons") are:
Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF")
FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")
Albert Cha ("Cha")
James Brush ("Brush")
Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>The address and principal business office of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304</principalBusinessOfficeOrResidenceAddress>        <citizenship>Entities:	      FLSPF 			        -	Delaware, U.S.A.
		      FHMLSP, L.P.		        -	Delaware, U.S.A.
		      FHMLSP, L.L.C.	        -	Delaware, U.S.A.
		      FLSPOF			        -	Delaware, U.S.A.
		      FHMLSP Overage, L.P.	-	Delaware, U.S.A.
		      FHMLSP, L.L.C.		-	Delaware, U.S.A.
		      FLS XI			        -	Delaware, U.S.A.
		      FHMLS XI, L.P.		        -	Delaware, U.S.A.
		      FHMLS XI, L.L.C.	        -	Delaware, U.S.A.
	              FLS X			        -	Delaware, U.S.A.
		      FHMLS X, L.P.   		-	Delaware, U.S.A.
		      FHMLS X, L.L.C.        	-	Delaware, U.S.A.

Individuals:    Topper       			-	United States Citizen
		      Heron			        -	United States Citizen
		      Cha			                -	United States Citizen
		      Brush			                -	United States Citizen
		      Estes			                -	United States Citizen</citizenship>      </item2>

        <item3>
		        <notApplicableFlag>Y</notApplicableFlag>

      </item3>



    <item4>
    <amountBeneficiallyOwned>The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</amountBeneficiallyOwned>    <classPercent>The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>

            <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>

    </item5>


        <item6>
	  	  <notApplicableFlag>Y</notApplicableFlag>
		        </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>

		<exhibitInfo>Exhibit 99.1	Joint Filing Agreement</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.P. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP, L.L.C.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences Public Overage Fund, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP Overage, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLSP Overage, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS X, L.L.C.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C.</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James N. Topper</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Patrick J. Heron</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Albert Cha </reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>James Brush</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Daniel Estes</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Steve R. Bailey</signature>
        <title>By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022</title>
        <date>02/14/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>


    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99-02142025_040249.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex-99-02142025_040249.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px" align="right"><b>EXHIBIT 99.1</b></p>
<p style="margin:0px" align="right"><br></p>
<p style="margin:0px" align="center"><b>JOINT FILING AGREEMENT</b></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:48px" align="justify">Pursuant to Rule&nbsp;13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule&nbsp;13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Eledon Pharmaceuticals, Inc.</p>
<p style="margin:0px; text-indent:48px" align="justify">&nbsp;</p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; padding-left:336px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLSP Overage, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLSP Overage, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px; font-family:Times New Roman Bold,Times New Roman" align="justify"><b>FHMLSP OVERAGE, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By FHMLSP Overage, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLSP OVERAGE, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br><br></p>
<hr style="margin-bottom: 9.6px; padding-top: 9.6px;" noshade size="1"><p style="page-break-before:always;margin-top:0;margin-bottom:-4pt;font-size:4pt"></p><p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS XI, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS XI, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FRAZIER LIFE SCIENCES X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.P., its General Partner</p>
<p style="margin:0px; text-indent:336px" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; padding-left:336px; text-indent:24px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.P.</b></p>
<p style="margin:0px; text-indent:336px; clear:left" align="justify">By: FHMLS X, L.L.C., its General Partner</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify"><b>FHMLS X, L.L.C.</b></p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; padding-left:336px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px" align="justify">Steve R. Bailey, Chief Financial Officer</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">James N. Topper</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>*</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Patrick J. Heron</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>**</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Albert Cha</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>**</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">James Brush</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By: <u>***</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Daniel Estes</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:336px; float:left">Date: &nbsp;February 14, 2025</p>
<p style="margin:0px; text-indent:-2px" align="justify">By:<u> /s/ Steve R. Bailey</u></p>
<p style="margin:0px; text-indent:360px; clear:left" align="justify">Steve R. Bailey, as Attorney-in-Fact</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">*This Joint Filing Agreement was executed by Steve&nbsp;R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">**This Joint Filing Agreement was executed by Steve&nbsp;R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify">***This Joint Filing Agreement was executed by Steve&nbsp;R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px" align="justify"><br><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
